Cystic fibrosis foundation commits up to an additional $24 million for prime medicine to develop gene editing therapy

Bethesda, md.--(business wire)--today, the cystic fibrosis foundation announced an additional investment of up to $24 million in prime medicine to continue the development of a gene editing therapy for people with cystic fibrosis (cf). prime medicine uses a gene editing technology called prime editing — a technology that enables a wide range of modifications to the dna with a high degree of precision. the company — founded by drs. david liu and andrew anzalone, who pioneered the development of.
PRME Ratings Summary
PRME Quant Ranking